marijuana stocks

Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

A live webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
jane.urheim@SternIR.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$MCIG Announces Richard Krueger as EVP of New Software Division

mCig(R) Inc. Launches Technology Division Led by Former MicroStrategy Exec., Richard Krueger…

$CGRW Announces LUA Approval

CannaGrow Holdings Announces LUA Approval and Issuance of CUP for Colorado Buffalo…

Cara Therapeutics, Inc. (CARA) Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA™

Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial…

CLS Holdings USA, Inc. (CLSH) Unveils Refreshed Company Website, Adding Third New Digital Asset for 2020

CLS Holdings USA, Inc. Unveils Refreshed Company Website, Adding Third New Digital…